Senate health committee meets with FDA commissioner nominee Heidi Overton
The Senate health committee held a meeting with Heidi Overton on Thursday regarding her nomination for FDA commissioner and her views on abortion medication.
Committee questions nominee on drug policy
During the Thursday session, lawmakers asked Heidi Overton about her stance on mifepristone. The nominee did not give a direct answer to these specific questions about the medication. Reports indicate she navigated around the issue when pressed by committee members.
Opposition groups express concern over views
Reproductive rights advocates stated they are worried Overton might use her position to restrict access to the drug. Some anti-abortion organizations had previously celebrated the nomination as a chance to challenge the medication. Critics note that mifepristone has faced legal challenges and congressional scrutiny for twenty years.
Safety record remains under review
Medical data shows the drug maintains a strong safety and efficacy record both in the United States and globally. Despite ongoing petitions and lawsuits, the medication continues to be used widely. The committee hearing marks another step in the long history of questioning this specific treatment.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.